| Prev Close | 400.81 |
| Day Low/High | 393.76 / 401.08 |
| 52 Wk Low/High | 271.37 / 442.00 |
| Avg Volume | 772.00K |
Regeneron Pharmaceuticals Inc. (REGN)
399.14
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 108.17M |
| Market Cap | 44.10B |
| EPS | 19.40 |
| P/E Ratio | 21.71 |
| Div & Yield | N.A. (N.A) |
Even Stocks With Bullish Outlooks Are Not Safe in the Market Carnage
Which means interest rate hikes are being built into prices.
Regeneron Shows a High Volume Bottom
Regeneron shows its relative strength in the market selloff.
How China's Troubles Affect Biotech and Pharma Stocks: Part 1
At first glance there is little connection, but you need to look deeper.
Odds Are Regeneron Rally Can Continue
My maximum risk can be defined below the July 27 low.
Finally, Respite From the Volatility
Still, momentum is cooling and valuation is an issue in more cases.
Stocks With Significant High Activity: the First Four Groups
There are some good buying ideas among these stocks.
The Market Reacts Rationally for Once
High-growth names, big commodity-takers, consumer plays shine today.
You Can Run, But You Can't Hide Today
There's no such thing as a 'safe harbor' right now on Wall Street.
Jim Cramer Won't Turn on Apple, Doesn't Like Twitter Until $19.20
Jim Cramer answers viewers' Twitter questions from the floor of the New York Stock Exchange.
Futures Tick Higher; Obama Pushes Emissions Reductions
Coal and renewables could both react as political and legal battles ensue.
Cramer: Biogen's Horseman May Have Fallen Off, I Like Others More
TheStreet's Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
When Leader Goes Down, Whole Sector Feels It
Biogen's weak numbers leave biotechs ailing.
Are Any New FANGs Baring Their Teeth?
The fearsome foursome have been reborn.
Cramer: Own Starbucks Over Dunkin, PayPal IPO Is a Buy Right Now
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
iShares Nasdaq Biotech ETF is Just What the Doctor Ordered for Your Portfolio
Technical factors point to a looming breakout for IBB.
Regeneron Reaches a Great Entry Point
This could be an opportune price to buy REGN, as it allows you to take a position fairly close to well-defined support.
Biotech Moves Are Anything But Crazy
New companies are coming up with major drugs.
A Stellar Day. But Why?
Bulls have the upper hand again.
Playing Biotechs with the House's Money
Here's how to lock in gains on risky small-cap biotechnology stocks.
Cramer: Intel Had to Be Aggressive With Altera, Don't Sell Amgen
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
What's Wrong With Betting on One Stock?
'Single-stock risk' is all the rage these days.
Why I'm Looking at Biotechs, Not Airlines
Cutthroat competition is good for customers, but not shareholders.
3 Biotechs That Are Worth Buying
Many of these stocks are off to the races.
The Second-Strongest Stock Market Sector Doesn't Jibe With the Strongest
You could throw darts at financials and health care and win.
Where to Invest to Shelter From the Market Rotation Crossfire
Some companies are so strong that they buck the rotation.
Cramer: I Like Receptos and Radius, as Well as the Four Horsemen
Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.
Janet Yellen, Stock Market Commentator?
It's not the Fed chief's place.
Here's What's Driving Biotech
And it's not the favorable macroeconomic climate.
I'm Going to Keep Riding These Horses
Biogen miss no reason to abandon big 4 of Big Pharma.
